BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sherman M, Bain V, Villeneuve JP, Myers RP, Cooper C, Martin S, Lowe C. The management of chronic viral hepatitis: A Canadian consensus conference 2004. Can J Infect Dis Med Microbiol 2004;15:313-26. [PMID: 18159509 DOI: 10.1155/2004/326964] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 O’leary C, Hong Z, Zhang F, Dawood M, Smart G, Kaita K, Wu J. A mathematical model to study the effect of hepatitis B virus vaccine and antivirus treatment among the Canadian Inuit population. Eur J Clin Microbiol Infect Dis 2010;29:63-72. [DOI: 10.1007/s10096-009-0821-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
2 Costiniuk CT, Mills E, Cooper CL. Evaluation of oral cannabinoid-containing medications for the management of interferon and ribavirin-induced anorexia, nausea and weight loss in patients treated for chronic hepatitis C virus. Can J Gastroenterol 2008;22:376-80. [PMID: 18414712 DOI: 10.1155/2008/725702] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
3 De Kaita K, Wong S, Renner E, Minuk GY. Treatment outcomes in a centralized specialty clinic for hepatitis C virus are comparable with those from clinical trials. Can J Gastroenterol 2006;20:87-90. [PMID: 16482233 DOI: 10.1155/2006/148962] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
4 Cox J, Morissette C, De P, Tremblay C, Allard R, Graves L, Stephenson R, Roy E. Access to sterile injecting equipment is more important than awareness of HCV status for injection risk behaviors among drug users. Subst Use Misuse 2009;44:548-68. [PMID: 19242863 DOI: 10.1080/10826080802544349] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
5 Chan AH, Partovi N, Ensom MH. The utility of therapeutic drug monitoring for ribavirin in patients with chronic hepatitis C--a critical review. Ann Pharmacother 2009;43:2044-63. [PMID: 19920162 DOI: 10.1345/aph.1M225] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
6 Bourrée F, Michel P, Salmi LR. [Consensus methods: review of original methods and their main alternatives used in public health]. Rev Epidemiol Sante Publique 2008;56:415-23. [PMID: 19013039 DOI: 10.1016/j.respe.2008.09.006] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
7 Bourrée F, Michel P, Salmi L. Consensus methods: Review of original methods and their main alternatives used in public health. Revue d'Épidémiologie et de Santé Publique 2008;56:e13-21. [DOI: 10.1016/j.respe.2008.10.005] [Cited by in Crossref: 23] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
8 Fischer B, Haydon E, Rehm J, Krajden M, Reimer J. Injection drug use and the hepatitis C virus: considerations for a targeted treatment approach--the case study of Canada. J Urban Health 2004;81:428-47. [PMID: 15273266 DOI: 10.1093/jurban/jth128] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 1.9] [Reference Citation Analysis]
9 Chayer M, Vieux M, Bruneau J, Jutras-aswad D. Traitement intégré de l’hépatite C auprès des personnes avec des troubles concomitants de santé mentale et de dépendance : promouvoir le changement en milieu urbain. smq 2011;36:77-96. [DOI: 10.7202/1008591ar] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
10 Buxton JA, Kim JH. Hepatitis A and hepatitis B vaccination responses in persons with chronic hepatitis C infections: A review of the evidence and current recommendations. Can J Infect Dis Med Microbiol 2008;19:197-202. [PMID: 19352452 DOI: 10.1155/2008/410362] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
11 Carvalho-Filho RJ, Dalgard O. Individualized treatment of chronic hepatitis C with pegylated interferon and ribavirin. Pharmgenomics Pers Med 2010;3:1-13. [PMID: 23226039 DOI: 10.2147/pgpm.s4461] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
12 Hong Z, Wu J, Smart G, Kaita K, Wen SW, Paton S, Dawood M. Survival analysis of liver transplant patients in Canada 1997-2002. Transplant Proc 2006;38:2951-6. [PMID: 17112872 DOI: 10.1016/j.transproceed.2006.08.180] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
13 Fischer B, Vasdev S, Haydon E, Baliunas D, Rehm J. Acceptabilité d’un traitement du virus de l’hépatite C chez des utilisateurs de drogues injectables au Canada. La Presse Médicale 2005;34:1209-12. [DOI: 10.1016/s0755-4982(05)84158-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]